European Archives - Page 1034 of 1469 - European Medical Journal

EMJ Dermatology 8 [Suppl 2] 2020

The 24th World Congress of Dermatology (WCD) and 28th European Academy of Dermatology and Venereology (EADV) Congress both delivered a host of symposia…

Biologics in Moderate-to-Severe Psoriasis: Discover the Road to Long-term Control

Advances in the treatment of moderate-to-severe psoriasis have accelerated considerably in the last 30 years. Prof Piaserico provided an overview of the…

Tildrakizumab in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analyses on Efficacy, Time to Relapse, Long-Term Safety in Elderly Population and Predictability From The reSURFACE 1 and reSURFACE 2 Phase III Clinical Trials

Psoriasis is a chronic, relapsing inflammatory skin disease, characterised in most cases by sharply demarcated, erythematous, pruritic plaques covered…

Long-Term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis through 3 Years (148 Weeks) from reSURFACE 1 and reSURFACE 2 Phase III Trials

IL-23 plays a key regulatory role in the pathogenesis of plaque psoriasis and medications targeting IL-23 have been shown to be effective for people with…

Hey Siri, can I trust you with my health?

While health tech is not set to drive pharma out of business, it is essential that the industry incorporates it into future strategies.

Gravitating towards planet centricity

It is time for the pharmaceutical industry to recognise their duty of care to the planet as well as patients, and drastically reduce their carbon footprint.

How do you solve a problem like pharma waste?

Amidst the public discourse surrounding sustainability and ethical practices, is the problem of pharmaceutical waste. It is imperative that the pharmaceutical industry actively seeks solutions.

Merz's Dr Terri L. Phillips on championing equality in the workplace

Dr Terri L. Phillips, Vice President and Head Global Medical Affairs, Merz, speaks to us about championing women in the workplace, her experience in the US army medical corps, and the changing nature of medical affairs.

Access to Medicine: Mission Possible

Globally, 5 billion people have access to medication, leaving 2 billion, predominantly in the developing world, who do not. As a challenge that only continues to grow in complexity, with ever-changing regulations and continual development of treatments, market access appears to be the pharmaceutical industry’s mission impossible

The history of pharma marketing

Over the past two centuries, the landscape of pharmaceutical marketing has transformed almost beyond recognition. We reflect on the propelling reasons behind such metamorphic change and consider the impact of emerging platforms: from print to radio and from TV to online.